{
    "2018-06-01": [
        [
            {
                "time": "2018-06-01",
                "original_text": "After Hours Most Active for Jun 1, 2018: ODP, PRSP, GME, ATUS$, QQQ, OKTA, ABBV, FOXA, GDDY, GM, ZNGA, MSFT",
                "features": {
                    "keywords": [
                        "Most Active",
                        "Jun 1",
                        "ABBV",
                        "MSFT"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-01",
                "original_text": "Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone",
                "features": {
                    "keywords": [
                        "IMBRUVICA",
                        "Phase 3",
                        "Treatment Outcomes",
                        "Waldenström's Macroglobulinemia"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-06-01",
                "original_text": "How Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Insurers",
                        "AbbVie",
                        "Sales"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-06-01",
                "original_text": "Solid Month Ends with New Round of Trade Fears",
                "features": {
                    "keywords": [
                        "Solid Month",
                        "Trade Fears"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "economy",
                        "global trade"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-06-01",
                "original_text": "Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Humira",
                        "EU panel nod"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}